<DOC>
	<DOCNO>NCT03027102</DOCNO>
	<brief_summary>This study aim determine safety toxicity incremental dos Double Negative T ( DNT ) cell human subject high risk acute myeloid leukemia ( AML ) . DNT cell mature T lymphocytes comprise ~1 % white blood cell human . Injection DNTs healthy donor demonstrate effective AML cell . DNT cell collect healthy volunteer inject patient .</brief_summary>
	<brief_title>Study Allogeneic Double Negative T Cells ( DNT-UHN-1 ) Patients With High Risk Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patient 1 . Patients AML 18 year age old . 2 . Viably frozen cell time diagnosis relapse available sensitivity test DNT cell . 3 . Patients give informed consent . 4 . Patients remission follow FLAGIda induction therapy receive consolidation treatment . 5 . Creatinine &lt; 1.5 x ULN within 7 day prior day 1 study treatment . 6 . AST , ALP , bilirubin &lt; 1.5x ULN within 7 day prior day 1 study treatment . 7 . Female patient childbearing potential willing use 2 method birth control ( Refer section 9.2.15 surgically sterile , abstain heterosexual activity course study day 1 1 month follow chemotherapy . Patients childbearing potential surgically sterilize free menses &gt; 2 year . Male patient use condom abstain sex time begin chemotherapy 1 month chemotherapy . 8 . Patients must able comply study procedure , minimum , DNTUHN1 cell system . Patient 1 . ECOG performance status &lt; 2 . 2 . Patients know persistent infection . 3 . Patients know active CNS disease . 4 . Life expectancy &lt; 3 month . 5 . Patients Cox2 inhibitor corticosteroid least 3 day prior 7 day infusion DNT cell . 6 . Patients HIV positive . 7 . Patients healthy donor DNT kill &lt; 10 % patient 's blast cell . Donor 1 . Has give write informed consent . 2 . Is 18 year age old . 3 . No known prior blood product transfusion surgery . 4 . Blood electrolyte ( Sodium , Potassium , Chloride , Bicarbonate , Magnesium , Phosphate , Calcium ) within normal range . 5 . Normal complete blood count . 6 . Normal liver kidney function ( Bilirubin , AST , ALT , ALP , LDH , plasma albumin , creatinine ) . 7 . Negative transfusion transmissible illness ( CMV , HIV I/II , HTLV I/II , Hepatitis B Surface Antigen , Hepatitis B Surface Antibody , Hepatitis B Core Antibody , Hepatitis C Antibody ) within 30 day blood collection DNT cell expansion patient infusion . 8 . Negative evidence exposure West Nile Virus , Syphilis within 30 day blood collection DNT cell expansion patient infusion . 9 . DNT cell expansion yield &gt; 108 per mL blood use standard protocol . Expanded DNT cell show â‰¥20 % cytotoxicity least 3 AML cell line ( MV411 AML3 , U937 ) . 10 . The donor meet donor inclusion/exclusion criterion , whose DNT cell show potent killing ( minimum &gt; 10 % kill ) AML patient 's blast cell ( blast cell frozen time diagnosis relapse ) approach participation study . Donor 1 . With history high risk behavior include , limited , history piercing ( except ear lobe ) , tattoo body modification . 2 . Has serious illness cardiovascular disease &amp; cancer . 3 . Has sexually transmissible disease . 4 . Has history intravenous drug use . 5 . Persons receive vaccination past 3 month prior enrolment study . 6 . Persons travel outside U.S. Canada past 3 year prior enrolment study , area consider endemic malaria . 7 . Persons receive blood component human tissue past 12 month prior enrolment study ( however may reduce 6 month nucleic acid testing ( NAT ) use test ) . 8 . Pregnant lactating . 9 . Persons risk transmit hematological immunological disease . 10 . Persons transmissible genetic disease family . 11 . On prescription medication . 12 . Persons prionrelated disease . 13 . Persons neurological disease unestablished etiology . 14 . Persons active encephalitis meningitis infectious unknown etiology . 15 . Persons rabies person , within past 6 month , bite animal treat animal rabid . 16 . Persons family history CreutzfeldtJakob disease . 17 . Persons receive humanderived pituitary growth hormone dura mata . 18 . Persons know suspected sepsis time donation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>allogenic double negative T cell</keyword>
	<keyword>DNT cell</keyword>
</DOC>